Rodopin Tablet 100 mg (Jotepin)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition, and the lowest effective dose possible should be administered. Adults: Administer zotepine 75∼150 mg per day orally in divided doses. The dose may be increased up to 450 mg per day depending on symptoms. If the daily dose is 300 mg or more, administer doses at intervals of at least 4 hours.

This medication should be used with caution in elderly patients or patients with dementia as it may increase mortality. Increased risk of cerebrovascular disease may occur, so special caution is required for patients with stroke risk factors. There is a risk of venous thrombosis, so it is important to check for risk factors for thrombosis and take preventive measures before and during the use of this medication. This medication should not be administered to certain patient populations such as those in a coma, experiencing hypotension, or with acute alcohol intoxication, and it should not be given to pregnant or breastfeeding women or children. Patients with various conditions such as brain disorders, liver disorders, blood disorders, heart disease, severe asthma, or seizure disorders should be given this medication with caution, as well as elderly patients or those in hot environments. This medication can lead to serious adverse reactions such as neuroleptic malignant syndrome, ECG abnormalities, paralytic ileus, seizure activities, and tardive dyskinesia, so treatment should be halted immediately if symptoms occur and appropriate medical care should be obtained. Drowsiness and decreased concentration may occur, so driving or operating hazardous machinery should be avoided, and there is a potential for blood abnormalities such as leukopenia, thus regular blood tests are necessary. Drug interactions may occur when combined with other medications, so consultation with a doctor or pharmacist is essential, especially not combining with certain medications. Pregnant or potentially pregnant women should not take this medication, and breastfeeding mothers should either stop breastfeeding or discontinue the medication. In case of overdose, severe symptoms such as central nervous system depression, hypotension, and seizures may occur, thus immediate medical treatment is necessary. This medication should be stored out of reach of children and care should be taken not to transfer it to other containers. Unexplained sudden deaths have been reported during treatment, so the patient's condition should be closely monitored during use.

Increased mortality rate, increased risk of cerebrovascular disease, venous thrombosis, worsening of coma, hypersensitivity reactions, hyperthermia, worsening of liver dysfunction, worsening of blood disorders, blood pressure fluctuations, respiratory depression, convulsions, high fever, malignant syndrome of neuromuscular relaxation, akinesia, severe muscle rigidity, dysphagia, tachycardia, sweating, leukocytosis, elevated serum creatine phosphokinase, myoglobinuria, decreased kidney function, consciousness disturbances, respiratory distress, circulatory collapse, dehydration symptoms, acute kidney failure, changes in electrocardiogram, intestinal paralysis, loss of appetite, nausea, vomiting, constipation, abdominal distension, seizure episodes, delayed dyskinesia, involuntary movements around the mouth, syndrome of inappropriate antidiuretic hormone secretion, hyponatremia, hyposmotic hyponatremia, increased sodium excretion in urine, hyperosmotic urine, Parkinson's syndrome, hand tremors, rigidity, muscle rigidity, decreased activity, gait disturbances, facial rigidity, mask-like facies, dyskinesia, dysarthria, eye-rolling seizures, postural abnormalities, inability to remain still, drowsiness, abnormal EEG, delirium, depression, insomnia, anxiety, agitation, restlessness, easily provoked, hypersexuality, increased talkativeness, exhaustion, posterior fossa syndrome, asthma, visual disturbances, sweat gland secretion disorders, weakness, fatigue, malaise, thirst, dizziness, headache, heaviness in head, nasal congestion, urinary difficulties, numbness, incontinence, sweating, urinary frequency, increased salivation, carbohydrate metabolism disorders, sexual dysfunction, menstrual irregularities, galactorrhea, corneal opacity, lens opacity, accommodative disorders, glaucoma, facial flushing, photosensitivity reactions, edema, rash, skin itching, eosinophilia, drug reactions, agranulocytosis, decreased serum uric acid, systemic lupus erythematosus-like symptoms, visual impairment, fever, taste disturbances, weight gain, weight loss, pupil dilation, drowsiness, central nervous system suppression, hypotension, extrapyramidal symptoms, intense emotions, emotional instability

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is important to store it at room temperature that is not too cold or too hot.

Appearance

This medication is a pale purple, sugar-coated tablet.

Package unit

30 tablets/bottle, 500 tablets/bottle